Regen BioPharma Inc (RGBP)

[jedijazz]

$RGBP Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen. "We did this and discovered dozens of new compounds that profoundly activated NR2F6. We are now selecting the best for further study."

"We are very excited at how well the medicinal chemistry program is working," says David Koos, Ph.D., Chairman & CEO Regen BioPharma Inc. "We will file additional composition of matter patents around these structures shortly and we should be able to focus on just one or two of the best ones moving forward."

About Regen BioPharma Inc.:

Regen BioPharma Inc. is a publicly traded biotechnology company (RGBP) and (RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.